Antibodies Industry Archives

Antibodies Industry | Forecast 2030

The antibodies industry data book is a combination of the market data from seven reports namely, antibodies production, polyclonal antibodies, monoclonal antibodies, cancer monoclonal antibodies, research antibodies, custom antibodies, and mammalian polyclonal IgG antibodies market. The antibodies production market was valued at USD 16.35 billion in 2022 with a CAGR of 12.92% during 2023-2030. The monoclonal antibodies market and research antibodies market is also growing at a CAGR of 11.04% and 4.76% respectively. Due to the increasing awareness and adoption of personalized medicine, the usage of targeted therapies has increased, thus pushing the revenues for monoclonal antibodies including cancer monoclonal antibodies.

antibodies production involves various processes including upstream process, downstream process, and filtration. The market is tracked based on the revenues generated through the manufacturing of these products. The monoclonal and research antibodies market tracks the end products that are commercially available in the market. The combination bundle of these reports is designed to provide a holistic view of these highly dynamic market spaces in the industry.

Access the Global Antibodies Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies

Antibody Production Market Growth & Trends

The global antibody production market size is anticipated to reach USD 42.86 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.92% from 2023 to 2030. Due to the rising incidence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases, as well as the increased need for therapeutic antibodies the antibody production market is anticipated a significant growth.

Polyclonal Antibodies Market Growth & Trends

The global polyclonal antibodies market size is anticipated to reach USD 2.21 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.01% from 2023 to 2030. The increasing technological advancements in the production of antibodies-based drugs, the growing prevalence of infectious & chronic diseases such as cancer across the globe, and the rising number of biopharmaceutical research and development activities are the main drivers of the industry. In addition, Polyclonal antibodies (pAbs) are extensively utilized in both quantitative and qualitative biological research as well as several diagnostic tests.

Order your copy of the Free Sample of “Life Science Microscopes Industry Data Book – Surgical, In-vitro Fertilization, Super Resolution And Scanning Electron Microscopes Market Size, Share, Trends Analysis And Segment Forecasts, 2022 – 2030, published by Grand View Research

Monoclonal Antibodies Market Growth & Trends

The global monoclonal antibodies market is projected to reach USD 494.53 billion by 2030, at a compound annual growth rate (CAGR) of 11.04% in the forecast period, according to a new report by Grand View Research, Inc. Increasing research and development activities aimed at the development of novel therapeutic monoclonal antibodies (mAbs) and supportive government initiatives for biologics production are anticipated to drive the market growth in the forecast period.

Cancer Monoclonal Antibodies Market Growth & Trends

The global cancer monoclonal antibodies market size is expected to reach USD 281.78 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.20% from 2023 to 2030. The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.

Research Antibodies Market Growth & Trends

The global research antibodies market size is expected to reach USD 2.21 billion by 2030, expanding at a CAGR of 4.76% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors driving the market include a rise in R&D activities undertaken by biopharmaceutical and biotechnology companies and increase in support from government authorities. Furthermore, expansion in the scope of neurobiology and stem cell research and the availability of technologically advanced antibody production methods are expected to propel market growth.

Custom Antibody Market Growth & Trends

The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness substantial growth during the forecast period. This growth is attributed to the increasing fundraising by biotech startups for developing innovative products. Additionally, rising awareness of personalized diagnostic and therapeutic treatments in emerging markets is also a contributing factor to the growth of the custom antibody market.

Mammalian Polyclonal IgG Antibody Market Growth & Trends

The global mammalian polyclonal IgG antibody market size is expected to reach USD 1.67 billion by 2030, registering a CAGR of 5.01% of the overall revenue, according to a new report by Grand View Research, Inc. The industry has witnessed significant growth owing to the development of innovative drugs and increasing government initiatives. Pharma and biotech companies are indulging in rigorous research and development since the antibody-drug conjugate is considered to be the fastest-growing field of the pharmaceutical market.In October 2022, SAB Biotherapeutics announced an exclusive partnership with Emergent BioSolutions Inc. According to the agreement, Emergent BioSolutions is expected to offer end-to-end services of Contract Development and Manufacturing (CDMO) to produce polyclonal antibody-based products.

Competitive Insights

Competitive rivalry in the antibodies industry is high due to the presence of a large number of both well-established players and small- to mid-sized companies as well as CROs in the market space. Some of the major players are Danaher Corporation, Thermo Fisher Scientific Inc., Sartorius AG, GE Healthcare, Eppendorf AG, Merck KGaA, Amgen Inc, Novartis AG, AstraZeneca plc, Abcam plc, F. Hoffman-La Roche Ltd., and Eli Lilly and Company among many others.

Antibodies Industry Data Book | Forecast 2030

Antibodies Industry Data Book – Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, Mammalian IgG Polyclonal Antibody Market

Grand View Research’s antibodies industry data book is a collection of market sizing & forecast insights, market dynamics & trends, opportunity assessment, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analysis studies. Within the purview of the data book, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research. The following data points will be included in the final product offering in Seven reports and one sector report overview.

Antibody Production Market Report Highlights

Based on product, the consumables segment dominated in terms of the revenue share of 55.93% in 2022. This is attributed to growing demand for antibodies for study, diagnostics, and therapeutics, which has steered to a corresponding rise in the demand for consumables

Based on process, the downstream segment dominated in terms of the revenue share of 67.04% in 2022 owing to the various technological advancements supporting the downstream process to maintain efficiency, thus, fueling innovations in bio-manufacturing, and hence, increasing the demand for the process in the antibody production market

In 2022, North America dominated with a revenue share of 38.29%, owing to the rising investments in drug discovery, growing developments in biopharmaceutical research, and the presence of major key players are anticipated to drive the growth of the antibody production market in this region

Order your copy of the Free Sample of “Antibodies Industry Data Book – Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030”, Data Book published by Grand View Research

Polyclonal Antibodies Market Report Highlights

Based on the product, the secondary antibodies segment dominated in terms of the revenue share of 56.14% in 2022, owing to the high sensitivity and enhanced signal amplification quality, thus increasing the demand in the industry

Based on end-user, the hospital & diagnostic centers segment dominates in terms of the revenue share of 59.81% in 2022. This is attributed to the increasing demand for pAbs-based assays in diagnostic centers and the rising prevalence of chronic & infectious diseases

Based on application, the diagnostics segment dominated in terms of the revenue share of 59.81% in 2022. Due to the ability of pAbs to recognize the epitopes of targeted molecules, it is regarded as the optimum reagent in hemagglutination assays and diagnostics. Thus, increasing the demand for diagnostics in the application segment

Monoclonal Antibodies Market Report Highlights

By source type, the human mAbs segment held the largest share of 54.3% in 2022 due to the low immunogenicity offered and increasing cancer treatment applications of these antibodies

In vitro production type held a dominating share of 76.9% in 2022 due to the low contamination levels offered by the technique and the availability of advanced bio-manufacturing capabilities

The oncology segment dominated the market in 2022 due to the rising number of approvals for mAb cancer therapeutics and increasing scientific and patient awareness about such therapies

Hospitals accounted for the largest share of the end-use segment in 2022 due to the widespread use of mAbs for cancer treatment in hospitals and increasing healthcare expenditure favoring the adoption of such therapeutics

Cancer Monoclonal Antibodies Market Report Highlights

By type, the humanized segment held a larger share of the market in 2021 owing to factors such as, low cost, availability, and quick production time for mouse monoclonal antibodies. However, the human segment is expected to hold the highest CAGR during the forecast period due to an increase in the number of product approvals and product launches

The blood cancer application segment held a significant revenue share in 2021 owing to an increase in the prevalence of hematological disorders along with a robust pipeline. In addition, the lung cancer segment is poised to expand at the highest CAGR during the forecast period

Research Antibodies Market Report Highlights

In 2022, the primary product segment held the largest revenue share due to the higher specificity and direct detection capabilities offered by the antibodies

By type, monoclonal antibodies captured a substantial share in 2022 due to the increase in COVID-19-related research activities involving the use of such antibodies

The western blotting technology segment held a dominant share of over 29.57% in 2022 because of the increasing investments in R&D activities by several biotechnology and pharmaceutical companies and the rapidly growing applications of antibodies in western blots created for proteomic studies

Custom Antibody Market Report Highlights

By type, the monoclonal antibody segment is considered to be a relatively more mature and dominant segment than polyclonal in 2022. The increasing R&D investment by companies is expected to support the growth of the custom antibody market

By service, the antibody development segment captured the majority of the custom antibody market share in 2022. The number and type of players in this service segment are greater than antibody production and fragmentation, which is contributing to the growth

By source, the mice segment is estimated to be the fastest-growing during the forecast period. This is because mice are widely available lab animals and can be easily used for custom antibody production